Apricus Biosciences Inc (APRI) : Traders are bullish on Apricus Biosciences Inc (APRI) as it has outperformed the S&P 500 by a wide margin of 25.41% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 19.7%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 20.33% in the last 1 week, and is up 22.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 16.18% and the 50-Day Moving Average is 18.69%.The 200 Day SMA reached 40.55% Apricus Biosciences, Inc. has dropped 8.41% during the last 3-month period . Year-to-Date the stock performance stands at -59.29%.
Apricus Biosciences Inc (APRI) : The highest short term price target forecast on Apricus Biosciences Inc (APRI) is $1 and the lowest target price is $1. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $0.88 with a standard deviation of $0.53.
For the current week, the company shares have a recommendation consensus of Buy. Apricus Biosciences Inc (NASDAQ:APRI): stock was range-bound between the intraday low of $0.4 and the intraday high of $0.445 after having opened at $0.44 on Fridays session. The stock finally closed in the red at $0.44, a loss of -7.84%. The stock remained in the red for the whole trading day. The total traded volume was 1,269,339 shares. The stock failed to cross $0.445 in Fridays trading. The stocks closing price on Thursday was $0.403.
Apricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Companys drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Companys other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Companys permeation enhancer for the treatment of Raynauds phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.